Health Trials

Clinical trials

4

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Intermediate- to High-Risk Non-Muscle-Invasive Bladder Cancer

This study aims to evaluate the efficacy and safety of intravenous administration of vedacitinib combined with intravesical instillation of mitomycin in treating patients with high-risk NMIBC with HER2 expression. The goal is to provide a new treatment option for NMIBC patients, reduce the risk of tumor recurrence, decrease the proportion of radical bladder surgery, and improve the quality of life of patients.

Participants needed: 30
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Shanxi Province Cancer HospitalUpdated: Jun 12, 2026Locations: 1
Eligibility criteria

Voluntary participation, signing a written informed consent form; [+8]

History of muscle-invasive bladder cancer or metastatic bladder cancer before tr... [+11]

Read more
Status: Not yet recruiting

Osimertinib Plus Capivasertib in NSCLC With PIK3CA/AKT1/PTEN Alterations Following Prior 1L Osimertinib

The goal of this clinical trial is to learn if Osimertinib plus Capivasertib works to treat EGFRm advanced non-small cell lung cancer (NSCLC) in participants with PIK3CA/AKT1/PTEN alterations after progression on first-line Osimertinib (monotherapy or plus chemotherapy). The main questions it aims to answer are: Part A: * Number of Dose-limiting toxicities (DLTs) * Adverse events (AEs)/serious adverse events (SAEs) (graded by CTCAE Version 5.0) * Recommended combined dose (RCD) Part B:Confirmed ORR assessed by the Investigator per RECIST 1.1 criteria. Participants will: Part A:Take Capivasertib twice daily from day 1 to 4 of a 7-day cycle, Osimertinib will be given orally QD(once daily) at 80 mg throughout the study treatment period. Part B: Take Osimertinib (80mg QD, continuously) and Capivasertib(RCD,orally BID from day1-day 4 in 7-day cycle , 4 days on /3 days off) till disease progression (PD) or unacceptable toxicity.

Participants needed: 53
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Shanxi Province Cancer HospitalUpdated: Mar 24, 2026Locations: 2
Eligibility criteria

Provision of signed and dated, written informed consent form (ICF) prior to any... [+31]

Patients harbouring concurrent actionable driver mutations with locally approved... [+28]

Read more
Status: Recruiting

Phase II Clinical Trial of Chidamide Combined With AK112 for Second-line and Advanced Bone and Soft Tissue Sarcoma

Evaluation of the efficacy and safety of Xidabenzamide combined with AK112 for advanced bone and soft tissue sarcoma of second-line and above.

Participants needed: 30
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Shanxi Province Cancer HospitalUpdated: Oct 15, 2024Locations: 1
Eligibility criteria

The patient voluntarily participated in this study and signed an informed consen... [+16]

Patients who have previously used sildenafil or other histone deacetylase inhibi... [+24]

Read more
Status: Not yet recruiting

A Single-arm, Single-center, Open-label Phase II Study of Zanubrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle CellLymphoma Patients

Evaluation the efficacy and safety of Zanubrutinib + R-CHOP/R-DHAP for the treatment mantle cell lymphoma.

Participants needed: 23
Trial details
Phase: Phase 2Age: 18-70Biological sex: AllType: InterventionalSponsor: Shanxi Province Cancer HospitalUpdated: Feb 13, 2024Locations: 1
Eligibility criteria

Histologically confirmed diagnosis of MCL according to WHO classification; [+16]

Known CNS involvement of MCL, Leukemic non-lymphonodular mantle cell lymphoma wa... [+14]

Read more